Trial Profile
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Oral Doses of LY2881835 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs LY 2881835 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- 26 Aug 2011 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 09 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 Jun 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.